



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/081,522	05/19/1998	PETER BROOKS	TSRI419OCONI	1607
7590 01/11/2005 THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD MAIL DROP TPC 8 LA JOLLA, CA 92037			EXAMINER GAMBEL, PHILLIP	
			ART UNIT 1644	PAPER NUMBER
DATE MAILED: 01/11/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Requested copies attached.

FD-302 (Rev. 11-27-70)

09/08/22

05/19/98

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	A01	5,766,391	6/16/98	Brooks et al.			
	A02						
	A03						
	A04						
	A05						
	A06						
	A07						
	A08						
	A09						

OTPE
FEB 23 2004

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PC	C01	Guthell, et al., "Targeted Antiangiogenic Therapy for Cancer Using vitaxin: A Humanized Monoclonal Antibody to the Integrin $\alpha_v\beta_3$ ", Clin.Cancer Research 6: 3056-3061 (2000).
	C02	
	C03	

EXAMINER	Phuoc Gmba 2/12/04	DATE CONSIDERED
----------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)	09/081522	
	Brooks et al.	
	FILING DATE 05/19/98	GROUP 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	A01	5,578,704	11/26/96	Kim			
	A02	5,652,109	7/29/97	Kim			
	A03	5,652,110	7/29/97	Kim			
	A04	5,677,181	10/14/97	Parish			
	A05	5,874,081	02/23/99	Parish			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	B01	WO 94/10331	5/11/94			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," <u>Cancer Research</u> 58: 485-490 (1998).
	C02	Carmeliet, "Integrin indecision," <u>Nature Medicine</u> 8: 14-16 (2002).
	C03	Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," <u>Proc. Natl. Acad. Sci USA</u> 84: 6471-6475 (1987).
	C04	Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" <u>Nature Medicine</u> 8: 193-194 (2002).
	C05	Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti $\alpha_5\beta_1$) Antibody in Patients with Metastatic Cancer," <u>Cancer Biotherapy & Radiopharmaceuticals</u> 16: 125-132 (2001).
	C06	Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," <u>Proc. Natl. Acad. Sci. USA</u> 95: 8910-8915 (1998).
	C07	Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β_1 integrin or β_2 and β_3 integrins," <u>Nature Medicine</u> 8: 27-34 (2002).
	C08	Schler et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," <u>J. Mol. Biol.</u> 255: 28-43 (1996).
PL	C09	Schler et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," <u>J. Mol. Biol.</u> 263: 551-567 (1996).


EXAMINER

Thurman

DATE CONSIDERED

4/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. TSR1 419.0 Coo 1		SERIAL NO. 09/081,522	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Brooks, et al			
				FILING DATE 5/19/98		GROUP 1644 1644	
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
Na		5,092,885	3/3/92	YAMADA ET AL.			
W		5,112,946	5/12/92	MALONE ET AL.			
W		5,192,744	3/9/93	BOUCK ET AL.			
W		5,202,352	4/13/93	OKADA ET AL.			
							

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
W		8905155	6/15/89	PCT			
W		0 576 898 A2	6/15/93	European Patent			
M		0 578 083 A2	6/26/93	European Patent			
M		8906356	7/27/89	PCT			
M		9320229	10/14/93	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Davis, et al., "Identification of a Role of the Vitronectin Receptor and Protein Kinase C in the Induction of Endothelial Cell Vascular Formation", <i>J. of Cell. Biochem.</i> 51: 206-218 (1993)
	2	Folkman, et al., "Angiogenic Factors", <i>Science</i> 235: 442-447 (1987)
	3	Moses, et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <i>Science</i> 248: 1408-1410 (1990)
	4	Folkman, et al., "Inhibition of Angiogenesis", <i>Cancer Res.</i> 52: 89-96 (1992)
	5	Blood, et al., "Tumor Interactions with the Vasculature: Angiogenesis and Tumor Metastasis", <i>Biochim. et Biophys. Acta</i> 1032: 89-118 (1990)
	6	Ingber, et al., "Inhibition of Angiogenesis through Modulation of Collagen Metabolism", <i>Lab. Invest.</i> 59 (1): 44-51 (1988)
	7	Aumailley, et al., "Arg-Gly-Asp Constrained within Cyclic Pentapeptides: Strong and Selective Inhibitors of Cell Adhesion to Vitronectin and Laminin-Fragment P1", <i>Fed. of Euro. Biochem. Soc.</i> 291 (1): 50-54 (1991)
	8	Choi, et al., "Inhibition of Neointimal Hyperplasia by Blocking $\alpha_5\beta_1$ Integrin with a Small Peptide Antagonist OpenGRGDSPCA", <i>J. of Vasc. Surg.</i> 19: 125-134 (1994)
	9	Nicosia, et al., "Inhibition of Angiogenesis in vitro by Arg-Gly-Asp-Containing Synthetic Peptide", <i>Amer. Jour. of Pathol.</i> 138 (4): 829-833 (1991)
	10	Cheresh, et al., "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor", <i>J. of Bio. Chem.</i> 262 (36): 17703-17711 (1987)
	11	Leavesley, et al., "Integrin β_1 - and β_3 -mediated Endothelial Cell Migration is Triggered through Distinct Signaling Mechanisms", <i>J. of Cell Biol.</i> 121: 163-170 (1993)
EXAMINER		DATE CONSIDERED
Grunger 4/9/01		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.
TSRJ 419.0 Con 1

SERIAL NO.
09/081,522

APPLICANT
Brooks, et al.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FILING DATE
5/19/98

GROUP
1648 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

21	Cheresh, et al., "Recognition of Distinct Adhesive Sites on Fibrinogen by Related Integrins on Platelets and Endothelial Cells", <i>Cell</i> 58: 945-953 (1989)
22	D'Amato, et al., "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci. USA</i> 91: 4082-4085 (1994)
23	Leibovich, et al., "Macrophage-induced Angiogenesis is Mediated by Tumour Necrosis Factor- α ", <i>Nature</i> 329: 630-632 (1987)
24	Pfaff, et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by $\alpha 5 \beta 1$ Integrins", <i>J. of Biol. Chem.</i> 269 (32): 20233-20238 (1994)
25	Yan, et al., "Human/Severe Combined Immunodeficient Mouse Chimeras: An Experimental in Vivo Model System to Study the Regulation of Human Endothelial Cell-Leukocyte Adhesion Molecules", <i>J. Clin. Invest.</i> 91: 986-996 (1993)
26	Gurrath, et al., "Conformation/Activity Studies of Rationally Designed Potent Anti-Adhesive RGD Peptides", <i>Eur. J. Biochem.</i> 210: 911-921 (1992)
27	Leven, et al., "Extracellular Matrix Stimulation of Guinea Pig Megakaryocyte Proplatelet Formation in vitro Is Mediated Through the Vitronectin Receptor", <i>Exp. Hematol.</i> 20: 1316-1322 (1992)
28	Lafronza, et al., "Up-regulated Biosynthesis and Expression of Endothelial Cell Vitronectin Receptor Enhances Cancer Cell Adhesion", <i>Canc. Res.</i> 52: 2202-2208 (1992)
29	Klein, et al., "Basic Fibroblast Growth Factor Modulates Integrin Expression in Microvascular Endothelial Cells", <i>Mol. Bio. of the Cell</i> 4: 973-982 (1993)
EXAMINER Gammal 4/9/01	
DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
MCA:WP/MSMER0046P.449

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO. TSRI 419.0 Con 1		SERIAL NO. 09081,522	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Brooks, et al.			
				FILING DATE 5/19/98		GROUP 1649 1644	
U.S. PATENT DOCUMENTS							
EXAM INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

12	12	Swerlick, et al., "Expression and Modulation of the Vitronectin Receptor on Human Dermal Microvascular Endothelial Cells", <u>J. of Invest. Derm.</u> 92 (5): 715-722 (1992)
13	13	Brooks, et al., "Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis", <u>J. of Cell Biol.</u> 122(6): 1351-1359 (1993)
14	14	Nip, et al., "Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin $\alpha\beta$, to Adhere to Lymph Node Vitronectin", <u>J. Clin. Invest.</u> 90: 1406-1413 (1992)
15	15	Jackson, et al., "Isolation and Propagation of Endothelial Cells Derived from Rheumatoid Synovial Microvasculature", <u>Ann. of the Rheu. Dis.</u> 48: 733-736 (1989)
16	16	Waldman, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy", <u>Science</u> 252: 1657-1662 (1991)
17	17	Brooks, et al., "Requirement of Vascular Integrin $\alpha\beta$, for Angiogenesis", <u>Science</u> 264: 569-570 (1994)
18	18	Chuntharapai, et al., "Blocking Monoclonal Antibodies to $\alpha V\beta 3$ Integrin: A Unique Epitope of $\alpha V\beta 3$ Integrin is Present on Human Osteoclasts", <u>Exper. Cell Res.</u> 205: 345-352 (1993)
19	19	Osbond, et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", <u>Imm. Today</u> 11 (6): 193-195 (1990)
20	20	Ausprunk, et al., "Vascularization of Normal and Neoplastic Tissues Grafted to the Chick Chorioallantois", <u>Amer. J. of Path.</u> 79 (3): 597-610 (1975)
EXAMINER <div style="display: flex; align-items: center;"> GMADEL 4/9/01 </div>		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
	FILING DATE May 19, 1998	GROUP 1644

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT



U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
PC	5,575,815	11/19/96	Slepian, et al.			
	5,849,692	12/15/98	Jonczyk, et al.			
	5,968,902	10/19/99	Scarborough, et al.			
	5,981,478	11/9/99	Ruoslahti, et al.			
	5,866,540	2/2/99	Jonczyk, et al.			
	5,135,919	8/4/92	Folkman, et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	95/28426	10/26/95	PCT			
	97/14716	4/24/97	PCT			
	0 770 622 A	5/2/97	EPO			
	89/06536	7/27/89	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994, <i>Circulation</i> , 90(5):2203-2205.
	2	Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996, <i>Eur. J. Cancer</i> , 32A(1):152-159.
	3	Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, <i>Biochem J.</i> , 300:729-736.
	4	Friedlander, et al., Definition of two angiogenic pathways by distinct α v integrins, 1995, <i>Science</i> , 270:1500-1502.
	5	Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins α IIb β 3, α v β 3 and α 5 β 1 and in cell adhesion inhibition, 1994, <i>Cell Adhes. Commun.</i> , 2(6):491-501.
	6	Smith, et al., Interaction of integrins α v β 3 and glycoprotein IIb-IIIa with fibrinogen, 1990, <i>J. Biol. Chem.</i> , 265:12267-12271.
	7	Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1991, 4(2):99-106.
	8	Ossowski, et al., Experimental model for quantitative study of metastasis, 1980, <i>Cancer Res.</i> , 40:2300-2309.
PC	9	Drake, et al., A antagonist of integrin α v β 3 prevent maturation of blood vessels during embryonic neovascularization, 1995, <i>J. Cell Sci.</i> , 108:2655-2661.

EXAMINER Philip Gmigel 5/28/01	DATE CONSIDERED
-----------------------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
	FILING DATE May 19, 1998	GROUP 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILED DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
PC	95/14714	6/1/95	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

PC	10	Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996, <i>Nature Med.</i> , 2(5):529-533.
	11	Brooks, et al., Integrin $\alpha v \beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994, <i>Cell</i> , 79:1157-1164.
	12	Clark, et al, Transient functional expression of $\alpha v \beta 3$ on vascular cells during wound repair, 1996, <i>Am. J. Pathol.</i> , 148:1407-1421.
	13	Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992, <i>J. Cell. Physiol.</i> , 153:437-449.
	14	Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992, <i>Seminars in Cancer Biology</i> , 3:57-63.
	15	Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993, <i>Int. J. Cancer</i> , 55:1023-1028.
	16	Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992, <i>Cell</i> , 69:11-25.
PC	17	Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha v \beta 3$, $\alpha v \beta 5$ and $\alpha v \beta 6$, 1994, <i>Cancer Res.</i> , 54:2102-2107.
EXAMINER Philip G. Gausa		DATE CONSIDERED 5/28/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSR1 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
	FILING DATE May 19, 1998	GROUP 1644



U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	RECEIVED OCT 15 2001 TECH CENTER 1600/2300

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

<i>N</i>	18	Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987, <i>J. Biol. Chem.</i> , 262:17294-17296.
<i>I</i>	19	Folkman, et al., Angiogenesis, 1992, <i>J. Biol. Chem.</i> , 267:10931-10934.
<i>I</i>	20	Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994, <i>Intl. J. Cancer</i> , 57:920-925.
<i>M</i>	21	Saiki, et al., Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly (RGD), 1990, <i>Jpn. J. Cancer Res.</i> , 81:668-675.
	22	
	23	
	24	
	25	
	26	
EXAMINER <i>PHILIP GAMBEL 5/28/02</i>		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.